Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

Phase 4

Completed

Conditions: Latent Tuberculosis
Diabetes Mellitus, Type 2

Interventions: Drug: Rifampicin 300 Mg Oral Capsule
Drug: Isoniazid 300 Mg ORAL TABLET

First Posted Date: 2021-04-05

Last Posted Date: 2023-05-16

Lead Sponsor: Herlev and Gentofte Hospital

Target Recruit Count: 32

Registration Number: NCT04830462

Locations: 🇩🇰
Herlev-Gentofte Hospital, Copenhagen, Denmark

The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028

Phase 1

Conditions: Healthy Male Volunteers

Interventions: Drug: SH-1028
Drug: Itraconazole
Drug: Rifampicin

First Posted Date: 2021-03-22

Last Posted Date: 2021-03-22

Lead Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT04808648

Locations: 🇨🇳
the First Affiliated Hospital with Bengbu Medical College, Bengbu, Anhui, China

Rifampicin at High Dose for Difficult-to-Treat Tuberculosis

Phase 2

Conditions: Tuberculosis

Interventions: Drug: Rifampin

First Posted Date: 2021-02-24

Last Posted Date: 2021-02-24

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 130

Registration Number: NCT04768231

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain
🇳🇱
University Medical Center, Groningen, Netherlands
🇵🇾
Instituto Nacional de Enfermedades Respiratorias y del Ambiente, Asunción, Paraguay

and more 2 locations

Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide

Phase 2

Suspended

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: rifampicin
Drug: pyrazinamide
Drug: HRZE
Drug: HR

First Posted Date: 2021-01-05

Last Posted Date: 2024-01-05

Lead Sponsor: University Hospital, Linkoeping

Target Recruit Count: 40

Registration Number: NCT04694586

Locations: 🇸🇪
Linköping University Hospital, Linköping, Sweden

Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

Phase 3

Recruiting

Conditions: Prosthetic Infection

Interventions: Drug: Rifabutin
Drug: Rifampicin

First Posted Date: 2020-12-17

Last Posted Date: 2022-05-10

Lead Sponsor: Tourcoing Hospital

Target Recruit Count: 436

Registration Number: NCT04672525

Locations: 🇫🇷
CHU Reims, Reims, France
🇫🇷
CH Annecy Genevois, Pringy, France
🇫🇷
Clinique de la Sauvegarde, Lyon, France

and more 27 locations

Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

Phase 1

Completed

Conditions: Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459

Interventions: Drug: Rifampin
Drug: SHR1459

First Posted Date: 2020-12-02

Last Posted Date: 2021-01-11

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT04649723

Locations: 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, Shanghai, China

A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Phase 2

Active, not recruiting

Conditions: Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Interventions: Drug: Bedaquiline
Drug: Clarithromycin
Drug: Ethambutol
Drug: Rifampicin
Drug: Rifabutin

First Posted Date: 2020-11-16

Last Posted Date: 2025-05-04

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 129

Registration Number: NCT04630145

Locations: 🇯🇵
Shimonoseki City Hospital, Yamaguchi, Japan
🇯🇵
National Hospital Organization Himeji Medical Center, Himeji, Japan
🇯🇵
Kinki-chuo Chest Medical Center, Sakai, Japan

and more 52 locations